



## Oncologia epato-bilio-pancreatica, Monza, 6 Maggio 2011



Luca Di Tommaso MD

La diagnosi istologica  
delle lesioni epatiche

University of Milan and IRCCS Istituto Clinico  
Humanitas, Rozzano, Milan


# Different focal lesions according to liver background

## Normal liver


HCC  
COLANGIO CA  
FOCAL NODULAR HYPERP  
ADENOMA  
METASTASES  
LYMPHOMA  
ABSCESS  
HEMANGIOMA  
FOCAL STEATOSIS

## Cirrhosis

HCC  
DN  
LRN  
METASTASES  
LYMPHOMA  
HEMANGIOMA



# Human hepatocarcinogenesis is multistep and takes time



Thorgeirsson SS, Grisham JW. Nat Genet 2002;31:339-346

SPECIAL ARTICLE

## **Pathologic Diagnosis of Early Hepatocellular Carcinoma: A Report of the International Consensus Group for Hepatocellular Neoplasia**

International Consensus Group for Hepatocellular Neoplasia

See Editorial on Page 355

**A**dvances in imaging techniques and establishment of surveillance protocols for high-risk populations have led to the detection of small hepatic nodules

chronic liver disease into large regenerative nodule, low-grade dysplastic nodule (L-DN), high-grade dysplastic nodule (H-DN), and HCC; this nomenclature has been

### ***Editorial by J Desmet***


## **East-West Pathology Agreement on Precancerous Liver Lesions and Early Hepatocellular Carcinoma**

See Article on Page 658

**T**he notion of cancer development as a multistep process, recognized in experimental liver carcinogenesis in rats,<sup>1</sup> also applies to human hepatocel-


be confused with large regenerative nodules, corresponding to nodules of  $\geq 5$  mm in diameter, larger than surrounding cirrhotic nodules, without atypia, and with no link to neoplasia. In contrast, HGDNs carry a worse prognosis with a four-fold risk of HCC development. They are characterized by clearly higher cell density than that of

# Dysplastic nodule



- Small sized (0,5-2 cm) grossly distinct nodule,
- 15 ~ 25% nodules in the cirrhotic liver under surveillance


# High grade Dysplastic Nodule




...showing a certain degree of cytological and architectural atypia but insufficient for a diagnosis of malignancy

# INCIDENCE & INCUBATION OF HCC IN pts WITH DN


(lavarone et al, personal communication)



# Small (<2 cm.), early HCC



# Small and Early HCC

A light micrograph of liver tissue. It shows several small, pale, irregular clusters of cells, which are the early stages of hepatocellular carcinoma. These clusters are surrounded by normal liver parenchyma, which appears as a dense pinkish-red background.


replacing pattern  
of growth

entrapped portal  
tracts

fatty changes

possible stromal but no  
vascular invasion

Small (< 2cm) and progressed HCC



## Small and progressed HCC

hypervascular pattern (arterial supply)

vascular invasion (25%)

clear round borders; expanding pattern of growth

# Clinical outcome of small HCC after surgical treatment


## early vs. progressed

	Early type	Progressed type
Average time to recurrence	3.9 yrs	1.7 yrs
5 year-survival	89 %	48 %

*Takayama T, Makuuchi M et al. Hepatology 1998*

Courtesy from  
M Kojiro (modified)

# Small HN, with not conclusive imaging



Uncertain for malignancy



HGDN/eHCC

Check malignancy by a biomarkers panel



ELSEVIER


Journal of Hepatology 50 (2009) 746–754

Journal of  
Hepatology


[www.elsevier.com/locate/jhep](http://www.elsevier.com/locate/jhep)

The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma<sup>☆</sup>

Luca Di Tommaso<sup>1</sup>, Annarita Destro<sup>2,†</sup>, Jae Yeon Seok<sup>3,†</sup>, Emanuela Balladore<sup>2</sup>, Luigi Terracciano<sup>4</sup>, Angelo Sangiovanni<sup>5</sup>, Massimo Iavarone<sup>5</sup>, Massimo Colombo<sup>5</sup>, Ja June Jang<sup>6</sup>, Eunsil Yu<sup>7</sup>, So Young Jin<sup>8</sup>, Emanuela Morenghi<sup>9</sup>, Young Nyun Park<sup>3,10,\*</sup>, Massimo Roncalli<sup>1,2,\*</sup>




H&E




GPC3

HCC: at least 2 markers staining



HSP70



GS

# Focal liver lesions in non hepatitic normal liver

Hepatocellular  
carcinoma

Liver cell adenoma

Hemangioma

Bile duct adenoma

Solitary necrotic nodules

Metastatic liver tumors


Angiomyolipoma

Epithelioid  
hemangioendothelioma

Angiosarcoma

Inflammatory pseudotumor

Focal nodular hyperplasia



# **Genotype–Phenotype Correlation in Hepatocellular Adenoma: New Classification and Relationship With HCC**

**Zuckman Rossi J et al Hepatology 2006;  
43:515-524**


**Hepatocellular Adenoma Subtype Classification Using  
Molecular Markers and Immunohistochemistry**

**Bioulac-Sage et al. Hepatology 2007; 46:740-748**

# HEPATOCYTOCELLULAR ADENOMA

<u>Type of Adenoma</u>	<u>Histology</u>	<u>Immunohistochemistry</u>
a) Steatotic	marked steatosis,	all negative
b) Atypical,	focal atypia	$\beta$ catenin & GS positive
c) Teleang/inflamm	infl+vess+duct	SAA positive
d) No specific trait		LFAB-P positive



# RISK OF MALIGNANT TRANSFORMATION



# Single HN, no cirrhosis

HISTOLOGICAL TYPE

RISK OF MALIGNANT  
TRANSFORMATION



# Focal liver lesions in non hepatitic normal liver

Hepatocellular  
carcinoma

Liver cell adenoma

Hemangioma

Bile duct adenoma

Solitary necrotic nodules

Metastatic liver tumors


Angiomyolipoma

Epithelioid  
hemangioendothelioma


Angiosarcoma

Inflammatory pseudotumor


Focal nodular hyperplasia







# LIVER METASTASES: PREVALENCE




# LIVER METASTASES, HISTOTYPE








COLORECTAL CARCINOMA






Cdx-2





EGFR


# CDX-2





BILIARY-PANCREATIC CARCINOMA






BREAST CARCINOMA



Estrogen receptor



c-erbB2


# ER e PgR

**Table 1. Estrogen Receptor (ER) and Progesterone Receptor (PR) Immunoreactivity in Tumors in the Liver**


Tumor Type	ER, No. (%)	PR, No. (%)
Breast (n = 17)	6 (35)	5 (29)
Hepatocellular carcinoma (n = 14)	0	1 (7)
Biliary (n = 16)	0	5 (31)
Esophageal/gastric (n = 16)	0	2 (13)
Colorectal (n = 14)	0	0
Pancreatic (n = 15)	0	1 (6)

- ER altamente specifico, ma poco sensibile
- PR poco specifico e poco sensibile
- Nelle mets. G3 poco utili entrambi

## LUNG CARCINOMA




- Positività di nucleo:
  - Carcinoma polmonare
  - Carcinoma tiroideo



# TTF-1

- Positività di citoplasma:
  - Epatociti
  - CCR, altri AdK






**Massimo Roncalli  
Annarita Destro  
Silvia Armenia**

*Pathology Unit &  
Research Labs, ICH and  
University of Milan*



**Marco Montorsi  
Guido Torzilli**

*Surgical Unit ICH and  
University of Milan*



**Nyun Young Park**  
*Yonsei  
University, Seoul*